Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

被引：0
|
作者：
Chen, Lei [1 ]
Latremouille-Viau, Dominick [2 ]
Guerin, Annie [2 ]
Nitulescu, Roy [2 ]
Gagnon-Sanschagrin, Patrick [2 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Anal Grp Inc, Montreal, PQ, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, Massimo
    Alimena, Giuliana
    BIODRUGS, 2011, 25 (03) : 147 - 157
  • [42] A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting
    Guerin, Annie
    Chen, Lei
    Wu, Eric Q.
    de Leon, Diego Ponce
    Griffin, James D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (07) : 1155 - 1162
  • [43] Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib
    Cole, Ashley L.
    Wood, William A., Jr.
    Muluneh, Benyam
    Lund, Jennifer L.
    Lafata, Jennifer Elston
    Dusetzina, Stacie B.
    JCO ONCOLOGY PRACTICE, 2020, 16 (05) : 243 - +
  • [44] First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
    D Rea
    G Etienne
    F Nicolini
    P Cony-Makhoul
    H Johnson-Ansah
    L Legros
    F Huguet
    M Tulliez
    M Gardembas
    K Bouabdallah
    P Rousselot
    J-M Cayuela
    F Guilhot
    F-X Mahon
    Leukemia, 2012, 26 : 2254 - 2259
  • [45] CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH METASTATIC COLORECTAL CANCER IN THE UNITED STATES: A HEALTHCARE CLAIMS DATABASE ANALYSIS
    Hsu, L., I
    Palanca-Wessels, M. C.
    Stecher, M.
    Siadak, M.
    Surinach, A.
    Arndorfer, S.
    DeBusk, K.
    VALUE IN HEALTH, 2021, 24 : S48 - S49
  • [46] First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
    Rea, D.
    Etienne, G.
    Nicolini, F.
    Cony-Makhoul, P.
    Johnson-Ansah, H.
    Legros, L.
    Huguet, F.
    Tulliez, M.
    Gardembas, M.
    Bouabdallah, K.
    Rousselot, P.
    Cayuela, J-M
    Guilhot, F.
    Mahon, F-X
    LEUKEMIA, 2012, 26 (10) : 2254 - 2259
  • [47] Comparasion Between Nilotinib and Dasatinib as Second-Line Therapy for Patients with Chronic Myeloid Leukemia: A Single Center Retrospective Study
    Lobo, Clarisse
    Boquimpani, Carla
    Madeira, Tania Silva
    Wendling, Patricia
    Maximo, Claudia
    Lima, Carlos Bernardo
    Atta, Plias
    Cravo, Kenata De Souza
    BLOOD, 2010, 116 (21) : 1411 - 1411
  • [48] RETROSPECTIVE CLAIMS ANALYSIS OF TREATMENT DURATION, HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH FIRST-LINE TREATMENT OF NSCLC WITH AFATINIB VS. ERLOTINIB IN THE UNITED STATES
    Samuelsen, C. H.
    Lim, J.
    Golembesky, A.
    Shrestha, S.
    Wang, L.
    Griebsch, I
    VALUE IN HEALTH, 2019, 22 : S81 - S81
  • [49] Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison
    Firwana, Belal
    Sonbol, Mohamad Bassam
    Diab, Maria
    Raza, Shahzad
    Hasan, Rim
    Yousef, Ibrahim
    Zarzour, Ahmad
    Garipalli, Archana
    Doll, Donald
    Murad, M. Hassan
    Al-Kali, Aref
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (06) : 1545 - 1553
  • [50] Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
    Juan Luis Steegmann
    Dolors Colomer
    Maria-Teresa Gómez-Casares
    Valentín García-Gutiérrez
    Guillermo Ortí
    Angel Ramírez-Payer
    Eduardo Olavarria
    Ferrán Vall-llovera
    Pilar Giraldo
    Eulogio Conde
    Rolando Vallansot
    Jose Luis López-Lorenzo
    Luis Palomera
    Alberto Álvarez-Larrán
    Venancio Conesa
    Guiomar Bautista
    Laura Casas
    Frank Giles
    Andreas Hochhaus
    Luis Felipe Casado-Montero
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 187 - 188
12345